What type of drug is Wegovy, and does that matter for your decision?

The decision most people arrive at before asking about drug type

A question our prescribers hear regularly goes something like: "I've heard about Wegovy but I don't really know what it actually is." That's a sensible place to pause. Knowing the drug class is not a technicality, it directly explains the side-effect profile, the interactions to watch for, and why weekly injections work differently from a daily diet pill.

Wegovy belongs to a group of medicines called GLP-1 receptor agonists. GLP-1 is a hormone released naturally from the gut after eating; it signals to the brain that food has arrived, prompting a feeling of fullness and triggering the pancreas to release insulin in a glucose-dependent way. Semaglutide is a synthetic analogue of that hormone, engineered to stay active in the body for around a week, which is why a single weekly injection is enough. The result is a sustained reduction in appetite rather than a sharp on-off signal. You can read more about how this mechanism plays out day-to-day on our semaglutide overview page.

One persistent misconception worth setting aside gently: Wegovy is not a stimulant. It does not speed up the heart or rev the nervous system to suppress hunger the way older appetite suppressants did. Its action is hormonal and peripheral, rooted in a pathway your body already uses. That distinction matters if you've read anything alarming about weight-loss drugs as a category, given that the biology of the drug semaglutide is quite different.

What the semaglutide drug type means for side effects and interactions

The GLP-1 drug class has a recognisable side-effect signature: predominantly gastrointestinal. Nausea, loose stools, constipation, indigestion and burping are the most commonly reported effects, especially in the early weeks of treatment or after a dose increase. They arise directly from slowed gastric emptying, the stomach is moving food into the small intestine more slowly than usual, which unsettles some people's digestion while their system adjusts. For most, these effects ease within a couple of weeks.

The same gastric-emptying mechanism is why the drug class has implications for oral medicines taken at the same time. NHS England's guidance on weight-management injections notes that women taking oral contraceptive pills alongside tirzepatide should add a barrier method during dose escalation; for semaglutide the evidence is less clear, but the principle is worth raising with your prescriber. The NHS guidance is worth reading in full if you take several medicines regularly.

A more serious but uncommon effect associated with GLP-1 receptor agonists is acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update highlighting this risk and advising anyone who experiences severe, persistent stomach pain (particularly pain that radiates toward the back) to seek urgent medical attention. The MHRA's Yellow Card scheme allows patients to report suspected side effects directly, which helps build the post-marketing evidence base for medicines in this class.

Semaglutide drug type: Wegovy versus Ozempic, the distinction that trips people up

Semaglutide exists in more than one licensed product in the UK, and the differences matter. Wegovy and Ozempic both contain semaglutide, but they are not interchangeable, they carry different licences, different dose schedules and different intended patient groups. Ozempic is licensed for type 2 diabetes management; Wegovy is licensed for weight management. Prescribing one for the other's indication is off-label, and for a prescription-only medicine that is a clinical decision with real consequences. If you want to understand what semaglutide type you are being prescribed and why it matters, the NHS medicines information explains the distinction clearly.

There is also now a third form: an oral tablet version of Wegovy, approved by the MHRA in June 2026, the first oral GLP-1 medicine licensed for weight management in the UK. Its dose schedule, absorption mechanism and practical requirements are different again from the injection. The underlying drug type is the same; the clinical detail is not.

If you are trying to decide between Wegovy and other options, or want to understand how the different semaglutide products relate to each other, our page on the different types of Wegovy available in the UK covers the landscape. And if you're curious how the GLP-1 class compares to tirzepatide (a dual GIP and GLP-1 receptor agonist) the weight-loss treatment overview sets out the clinical picture without steering you toward one or the other before you've spoken to anyone.

What the drug class tells you about eligibility, and what it doesn't

The licensed indication for Wegovy in the UK covers adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. That is the clinical territory defined by the licence. What it does not tell you is whether Wegovy is the right choice for you specifically, your medical history, current medicines, previous treatments and personal circumstances all feed into that assessment.

NICE's appraisal of semaglutide for weight management (TA875) sets its own criteria for NHS access, which are stricter than the licence alone. Private prescribing follows the licensed indication, but a prescriber still evaluates the whole picture. The drug class matters here too: certain conditions (a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis) require careful discussion before any GLP-1 medicine is started.

Understanding Wegovy as a GLP-1 receptor agonist tells you a great deal. It does not replace a conversation with a clinician who knows your situation. If you want to explore whether it could be suitable, checking your eligibility through a free consultation with our GPhC-registered prescribers is the right starting point.